Non-Interventional Post-Authorisation Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines (EV-010)
France
Germany
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS48390
First published:
13/05/2026
Study
Ongoing
Post-authorisation observational safety study to examine the effectiveness of risk minimization measures in place in persons with an Anapen® prescription (PASS 21-08)
France
EU PAS number:
EUPAS1000000972
First published:
13/05/2026
Study
Planned
Long-term, Non-interventional Study of Recipients of Yescarta® for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, and Follicular Lymphoma
Austria
Canada
Czechia
France
Germany
Israel
Italy
Netherlands
Poland
Portugal
Spain
Switzerland
United Kingdom
United States
EU PAS number:
EUPAS32539
First published:
13/05/2026
Study
Ongoing
DARWIN EU® - Time to onset of thromboembolic events in adults with selected types of cancer
Belgium
Denmark
Estonia
Finland
Germany
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS1000000814
First published:
13/05/2026
Study
Finalised
DARWIN EU® - Assessing the potential association between venlafaxine and heart failure in adults
Denmark
Finland
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS1000000974
First published:
13/05/2026
Study
Ongoing
TARGET-EU: Effectiveness of BNT162b2 mRNA COVID-19 vaccine in healthy individuals or with stable pre-existing medical conditions against SARS-CoV-2 infection
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS1000000995
First published:
12/05/2026
Study
Ongoing
Comparative Effectiveness of Ticagrelor vs. Prasugrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Australia
Korea, Republic of
United States
EU PAS number:
EUPAS1000000551
First published:
12/05/2026
Study
Ongoing
DARWIN EU® - Capturing obesity in DARWIN EU
Belgium
Croatia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Italy
Netherlands
Norway
Portugal
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS1000000820
First published:
12/05/2026
Study
Planned
Post-Authorisation Safety Study of Paediatric Patients Initiating Selumetinib: A Multiple-Country Prospective Cohort Study
Austria
France
Germany
Israel
Italy
Netherlands
Portugal
Spain
Switzerland
United Kingdom
EU PAS number:
EUPAS45972
First published:
11/05/2026
Study
Ongoing
TARGET-EU: Clinical benefit of bevacizumab in metastatic colorectal cancer
Netherlands
EU PAS number:
EUPAS1000000996
First published:
11/05/2026
Study
Ongoing
TARGET-EU: Risk of adverse birth and neurodevelopmental outcomes in children born alive to fathers exposed to valproate versus levetiracetam for generalised epilepsy
Netherlands
Spain
EU PAS number:
EUPAS1000000999
First published:
11/05/2026
Study
Planned
TAK-755-4007: A Post-Authorization Safety Study (PASS) to Further Evaluate Real-World Safety in Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated with Adzynma
Austria
France
Germany
Italy
Poland
Spain
Switzerland
United Kingdom
EU PAS number:
EUPAS1000000870
First published:
11/05/2026
Study
Planned
Implementation of controlled access to and distribution of medicinal products in European Union (CONTROL-EU)
Austria
Greece
Latvia
Netherlands
Portugal
Slovenia
Spain
Sweden
EU PAS number:
EUPAS1000000313
First published:
11/05/2026
Study
Finalised
Registry to Document Treatment Effectiveness, Safety, Including Prospective Long-term Outcomes in Participants with Progressive Familial Intrahepatic Cholestasis (PFIC) who take Odevixibat (Bylvay)
China
EU PAS number:
EUPAS1000000975
First published:
11/05/2026
Study
Ongoing
COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER)
Australia
Bulgaria
Canada
Colombia
Croatia
Cyprus
Denmark
Germany
Greece
Hong Kong
Italy
Korea, Republic of
Malaysia
Mexico
New Zealand
Nigeria
Philippines
Romania
Singapore
Slovakia
Slovenia
South Africa
United Kingdom
United States
EU PAS number:
EUPAS39096
First published:
08/05/2026
Study
Ongoing
Real-world experience of children with growth hormone deficiency who switched from daily growth hormone to the Long-Acting Growth Hormone Somatrogon
Czechia
Israel
EU PAS number:
EUPAS1000000829
First published:
08/05/2026
Study
Ongoing
Post Conditional Approval Active Surveillance Study Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine
Italy
Netherlands
Norway
Spain
United Kingdom
EU PAS number:
EUPAS41623
First published:
08/05/2026
Study
Finalised
Real World Use, Effectiveness and Safety of Romosozumab among Osteoporosis Patients in Guangdong China (20250009)
China
EU PAS number:
EUPAS1000000758
First published:
08/05/2026
Study
Planned
Retrospective analysis of adolescent patients suffering from hereditary angioedema treated with berotralstat in Europe: patients’ and treatment characteristics
Belgium
France
Germany
Italy
Spain
United Kingdom
EU PAS number:
EUPAS1000000997
First published:
08/05/2026
Study
Planned
A Post-Authorization Safety Study of Guillain-Barré Syndrome (GBS) Following ABRYSVOTM Among Older Adults in the United States (C3671031)
United States
EU PAS number:
EUPAS1000000753
First published:
08/05/2026
Study
Planned
Prospective Non-Interventional Study Evaluating the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS)
European Union
EU PAS number:
EUPAS1000000961
First published:
08/05/2026
Study
Planned
EMR200098_008: Prospective and retrospective, single-cohort, multicenter observational long-term study in short children born small for gestational age (SGA) after treatment with Saizen® or with other recombinant human growth hormone (r-hGH) products (SALTO)
France
Germany
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS16520
First published:
08/05/2026
Study
Discontinued
id.DRIVE surveillance study of respiratory pathogens in adults hospitalised for severe acute respiratory infection (SARI) across Europe
France
Germany
Italy
Spain
United Kingdom
EU PAS number:
EUPAS1000000012
First published:
08/05/2026
Study
Ongoing
id.DRIVE study of brand-specific respiratory syncytial virus (RSV) vaccine effectiveness in Europe
France
Germany
Italy
Spain
United Kingdom
EU PAS number:
EUPAS1000000035
First published:
08/05/2026
Study
Ongoing
A regulatory non-interventional study to monitor the safety and efficacy of JARDIANCE® (Empagliflozin 10 mg) in Korean patients with Chronic Kidney Disease (CKD)
Korea, Republic of
EU PAS number:
EUPAS107293
First published:
08/05/2026
Study
Finalised
An Observational Study of Ocrelizumab Treated Patients with Multiple Sclerosis to Determine the Incidence and Mortality Rates of Breast Cancer and All Malignancies (VERISMO Study)
Germany
United States
EU PAS number:
EUPAS30752
First published:
08/05/2026
Study
Ongoing
Belzutifan special drug use results survey in von Hippel-Lindau (VHL) disease-associated tumors: a post-authorization safety study (PASS) (MK-6482-046)
Japan
EU PAS number:
EUPAS1000000881
First published:
08/05/2026
Study
Planned
Prospective Registry-Based Study Evaluating the Effectiveness and Safety of Odevixibat in Participants With Alagille Syndrome (ALGS)
United States
EU PAS number:
EUPAS1000000441
First published:
08/05/2026
Study
Ongoing
Belzutifan special drug use results survey in radically unresectable or metastatic renal cell carcinoma: a postauthorization safety study (PASS) (MK-6482-045)
Japan
EU PAS number:
EUPAS1000000880
First published:
08/05/2026
Study
Planned
Effectiveness and Safety of Avacopan as Add-on to Standard of Care (SOC) Versus SOC Alone in ANCA-associated Vasculitis (LIBRA) (20240051)
United States
EU PAS number:
EUPAS1000000985
First published:
08/05/2026
Study
Ongoing
Safety and effectiveness of RZV in adults ≥18 years of age with Systemic lupus erythematosus (SLE) or Multiple sclerosis (MS) (EPI-ZOSTER-041 VS US DB 215104)
United States
EU PAS number:
EUPAS107073
First published:
08/05/2026
Study
Ongoing
DARWIN EU® - Characterising the use of JAK inhibitors in Europe: a Drug Utilisation Study Update
Croatia
Denmark
Finland
Germany
Spain
Sweden
EU PAS number:
EUPAS1000000998
First published:
08/05/2026
Study
Ongoing
Frequency of HIV diagnoses among people using oral and LA PrEP (223555)
United States
EU PAS number:
EUPAS1000000371
First published:
06/05/2026
Study
Ongoing
Post-Approval Observational Cohort Study to Evaluate the Safety of the COMIRNATY 2023-2024 Formula in the United States
United States
EU PAS number:
EUPAS108135
First published:
06/05/2026
Study
Finalised
DARWIN EU® - Enabling pregnancy and mother-child research in DARWIN EU® Data Network - PeriNet
Croatia
Denmark
Finland
France
Germany
Hungary
Netherlands
Norway
Portugal
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS1000000812
First published:
06/05/2026
Study
Ongoing
A study to assess utilisation and safety of Glycopyrronium Bromide 1mg/5ml Oral Solution as licensed for symptomatic treatment of severe sialorrhoea in children and adolescents aged 3 years and older with chronic neurological disorders in the UK
United Kingdom
EU PAS number:
EUPAS103644
First published:
05/05/2026
Study
Finalised
Patient Characteristics and Elranatamab administration patterns of Real-World Patients Receiving Elranatamab
United States
EU PAS number:
EUPAS1000000853
First published:
05/05/2026
Study
Planned
Vedolizumab-4081: Infection Outcomes among Advanced Therapy-naive Older Adult US Patients With UC/CD Initiating ENTYVIO, TNF-alpha Inhibitors, or Ustekinumab: A Retrospective Observational Matched-Cohort Study Using Medicare Claims Data, 2016-2025
United States
EU PAS number:
EUPAS1000000767
First published:
05/05/2026
Study
Ongoing
A prospective study to evaluate the safety, effectiveness and impact of the RTS, S/AS01E vaccine in young children in sub-Saharan Africa (EPI-MALARIA-003 VS AME)
Ghana
Kenya
Malawi
EU PAS number:
EUPAS28541
First published:
04/05/2026
Study
Ongoing
Post-marketing Safety Study of mRNA-1283 in the United States
United States
EU PAS number:
EUPAS1000000971
First published:
04/05/2026
Study
Planned
Compare data sources